| Primary |
| Low Back Pain |
12.9% |
| Multiple Sclerosis |
9.5% |
| Angioimmunoblastic T-cell Lymphoma |
9.1% |
| Back Pain |
7.3% |
| Prophylaxis Against Transplant Rejection |
7.3% |
| Renal Transplant |
6.5% |
| Rheumatoid Arthritis |
6.5% |
| Pain |
4.3% |
| Systemic Lupus Erythematosus |
4.3% |
| Immunosuppression |
3.9% |
| Acute Lymphocytic Leukaemia |
3.4% |
| Primary Mediastinal Large B-cell Lymphoma |
3.4% |
| Lumbar Spondylosis |
3.0% |
| Transplant Rejection |
3.0% |
| Anaemia Haemolytic Autoimmune |
2.6% |
| Chronic Myeloid Leukaemia |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Graft Versus Host Disease |
2.6% |
| Ill-defined Disorder |
2.6% |
| T-cell Lymphoma Stage Iv |
2.6% |
|
| Meningitis |
10.4% |
| Product Contamination |
9.1% |
| Atrial Fibrillation |
8.4% |
| Injection Site Abscess |
7.8% |
| Hospitalisation |
7.1% |
| Vomiting |
7.1% |
| Product Quality Issue |
6.5% |
| Neutropenia |
5.2% |
| Medication Error |
4.5% |
| Pyrexia |
3.9% |
| Tumour Lysis Syndrome |
3.9% |
| Epidural Lipomatosis |
3.2% |
| Injection Site Infection |
3.2% |
| Vision Blurred |
3.2% |
| Wrong Drug Administered |
3.2% |
| Hepatic Necrosis |
2.6% |
| Hepatitis |
2.6% |
| Nausea |
2.6% |
| Neutropenic Sepsis |
2.6% |
| No Adverse Event |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
16.6% |
| Rheumatoid Arthritis |
11.0% |
| Prophylaxis Against Renal Transplant Rejection |
9.3% |
| Immunosuppression |
6.6% |
| Pyrexia |
6.6% |
| Acute Lymphocytic Leukaemia |
6.4% |
| B-cell Lymphoma |
4.6% |
| Asthma |
4.3% |
| Prophylaxis Against Transplant Rejection |
4.3% |
| Diffuse Large B-cell Lymphoma |
4.1% |
| Infection |
3.7% |
| Pain |
3.1% |
| Acute Myeloid Leukaemia |
2.9% |
| Myelodysplastic Syndrome |
2.9% |
| Premedication |
2.9% |
| Lymphoma |
2.5% |
| Multiple Myeloma |
2.3% |
| Systemic Lupus Erythematosus |
2.1% |
| Acute Leukaemia |
1.9% |
| Low Back Pain |
1.9% |
|
| Pleural Effusion |
8.1% |
| Drug Ineffective |
6.8% |
| Hospitalisation |
6.8% |
| Thrombotic Microangiopathy |
6.8% |
| Gastrointestinal Haemorrhage |
5.4% |
| Meningitis |
5.4% |
| Progressive Multifocal Leukoencephalopathy |
5.4% |
| Pulmonary Embolism |
5.4% |
| Tuberculosis |
5.4% |
| Atrial Fibrillation |
4.1% |
| Breast Cancer |
4.1% |
| Fibrin D Dimer Increased |
4.1% |
| Injection Site Infection |
4.1% |
| Nasopharyngitis |
4.1% |
| Osteonecrosis |
4.1% |
| Pain In Extremity |
4.1% |
| Peliosis Hepatis |
4.1% |
| Sepsis |
4.1% |
| Vasculitis Cerebral |
4.1% |
| Viith Nerve Paralysis |
4.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.5% |
| Rheumatoid Arthritis |
15.4% |
| Drug Use For Unknown Indication |
14.3% |
| Asthma |
4.0% |
| Premedication |
3.9% |
| Hypertension |
3.3% |
| Prophylaxis |
3.3% |
| Arthritis |
2.9% |
| Contraception |
2.3% |
| Joint Swelling |
2.1% |
| Oedema Peripheral |
2.1% |
| Myositis |
2.1% |
| Pain |
2.0% |
| Osteoporosis |
1.6% |
| Immunosuppression |
1.4% |
| Acute Myeloid Leukaemia |
1.3% |
| Glioblastoma |
1.2% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
| Premenstrual Syndrome |
1.1% |
| Bronchitis |
1.0% |
|
| White Blood Cell Count Increased |
9.8% |
| Pulmonary Embolism |
8.6% |
| Progressive Multifocal Leukoencephalopathy |
8.0% |
| Large Intestine Perforation |
7.5% |
| Allergic Granulomatous Angiitis |
6.9% |
| Staphylococcal Infection |
6.3% |
| Cholelithiasis |
4.6% |
| Renal Failure Acute |
4.6% |
| Fall |
4.0% |
| Pain |
4.0% |
| Respiratory Failure |
4.0% |
| Toxic Skin Eruption |
4.0% |
| Urinary Tract Infection |
4.0% |
| Asthma |
3.4% |
| Mitral Valve Incompetence |
3.4% |
| Mucosal Dryness |
3.4% |
| Oedema Peripheral |
3.4% |
| Pleural Effusion |
3.4% |
| Pneumonia |
3.4% |
| Aggression |
2.9% |
|
| Interacting |
| Drug Use For Unknown Indication |
100.0% |
|
|
